Multi-analyte ADC PK/PD and exposure-driven dose selection — therapeutic window and OBD from conjugate efficacy vs. free-payload toxicity, the toxicology paradigm (not MABEL).
adc dar pkpd immuno-oncology pkpd-modelling antibody-drug-conjugates dose-selection multi-analyte therapeutic-index
-
Updated
Jul 2, 2026 - Python